Current Report Filing (8-k)
December 20 2021 - 11:08AM
Edgar (US Regulatory)
0001589150 false 0001589150 2021-12-13
2021-12-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT
REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): December
13, 2021
REGEN BIOPHARMA, INC.
(Exact name
of small business issuer as specified in its charter)
Nevada |
45-5192997 |
(State or
other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) |
Commission File
No. 333-191725
4700 Spring Street, St
304, La
Mesa, California 91942
(Address of
Principal Executive Offices)
(619) 722
5505
(Issuer’s
telephone number)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered
pursuant to Section 12(b) of the Act:
Title
of each class |
Trading
Symbol(s) |
Name of
each exchange on which registered |
|
None |
|
Indicate by
check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
As of June 30, 2021 Regen Biopharma, Inc. ( the “Company”) had
principal indebtedness on convertible notes of $2,364,075 . Between
July 1, 2021 and December 13, 2021 the Company satisfied $1,023,454
of principal indebtedness on convertible notes. As of December 13,
2021 principal indebtedness on convertible notes was
$1,340,621.
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
REGEN BIOPHARMA,
INC. |
|
|
Dated:
December 20, 2021 |
By: /s/ David
Koos |
Regen Biopharma (PK) (USOTC:RGBP)
Historical Stock Chart
From Jan 2023 to Feb 2023
Regen Biopharma (PK) (USOTC:RGBP)
Historical Stock Chart
From Feb 2022 to Feb 2023